Extract

The primary objective of this study is to determine the progression-free survival and objective response rate (complete + partial responses) of subjects with stage IIIB with pleural effusion or IV non-small cell lung cancer treated with paclitaxel and carboplatin plus either tamibarotene or matching placebo.

Inclusion criteria

• Advanced non-small-cell lung cancer

Links

• euctr
• ictrp